



S3 Fig. Leptomeningeal or dural metastasis-free survival (LMCDM-FS) according to the systemic treatments in human epidermal growth factor receptor 2 (HER2)-positive (n=31) (A) and HER2-negative (n=20) (B) subgroups of patients. In patients with HER2-positive primary tumor, targeted therapy (Targeted Tx) with or without chemotherapy (CTx), CTx, and no systemic treatment (Tx) were compared. In patients with HER2-negative primary tumor, CTx was compared with no systemic Tx.